Vanda Pharmaceuticals Inc. - Amended Statement of Ownership (SC 13G/A)
08 3월 2008 - 7:20AM
Edgar (US Regulatory)
|
|
|
|
UNITED
STATES
|
|
|
SECURITIES
AND EXCHANGE COMMISSION
|
|
|
Washington, D.C. 20549
|
|
|
|
|
SCHEDULE
13G
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULES 13d-1(b), (c), AND (d) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Vanda
Pharmaceuticals Inc.
(Name of Issuer)
(Title of Class of Securities)
(CUSIP Number)
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:
o
|
Rule 13d-1(b)
|
x
|
Rule 13d-1(c)
|
o
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be
filled out for a reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing
information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of
this cover page shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 921659108
|
|
|
1.
|
Names
of Reporting Persons
Versant Capital Management LLC
|
|
|
2.
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
(a)
|
o
|
|
|
(b)
|
o
|
|
|
3.
|
SEC
Use Only
|
|
|
4.
|
Citizenship
or Place of Organization
Delaware
|
|
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole
Voting Power
0 shares of Common Stock
|
|
6.
|
Shared
Voting Power
0 shares of Common Stock
|
|
7.
|
Sole
Dispositive Power
0 shares of Common Stock
|
|
8.
|
Shared Dispositive Power
0 shares of Common Stock
|
|
|
9.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
0 shares of Common Stock
|
|
|
10.
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
o
|
|
|
11.
|
Percent
of Class Represented by Amount in Row (9)
0.0%
|
|
|
12.
|
Type
of Reporting Person (See Instructions)
OO
|
|
|
|
|
|
|
2
CUSIP
No. 921659108
|
|
|
1.
|
Names
of Reporting Persons
Herriot Tabuteau
|
|
|
2.
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
(a)
|
o
|
|
|
(b)
|
o
|
|
|
3.
|
SEC
Use Only
|
|
|
4.
|
Citizenship
or Place of Organization
United States
|
|
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole
Voting Power
0 shares of Common Stock
|
|
6.
|
Shared
Voting Power
0 shares of Common Stock
|
|
7.
|
Sole
Dispositive Power
0 shares of Common Stock
|
|
8.
|
Shared Dispositive Power
0 shares of Common Stock
|
|
|
9.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
0 shares of Common Stock
|
|
|
10.
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
o
|
|
|
11.
|
Percent
of Class Represented by Amount in Row (9)
0.0%
|
|
|
12.
|
Type
of Reporting Person (See Instructions)
IN
|
|
|
|
|
|
|
3
CUSIP
No. 921659108
|
|
Item 1.
|
|
(a)
|
Name
of Issuer
Vanda Pharmaceuticals Inc.
|
|
(b)
|
Address
of Issuers Principal Executive Offices
9605 Medical Center Drive
Suite
300
Rockville,
MD 20850
|
|
Item 2.
|
|
(a)
|
Name
of Person Filing
Versant Capital Management LLC
Herriot
Tabuteau
|
|
(b)
|
Address
of Principal Business Office or, if none, Residence
Versant Capital Management LLC
45
Rockefeller Plaza
Suite
2074
New
York, New York 10111
Herriot
Tabuteau
c/o
Versant Capital Management LLC
45
Rockefeller Plaza
Suite
2074
New
York, New York 10111
|
|
(c)
|
Citizenship
See Item 4 of cover pages
|
|
(d)
|
Title
of Class of Securities
Common Stock, par value $.01 per share
|
|
(e)
|
CUSIP
Number
921659108
|
|
Item 3.
|
If this
statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check
whether the person filing is a:
|
|
(a)
|
o
|
Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
(b)
|
o
|
Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
(c)
|
o
|
Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
(d)
|
o
|
Investment
company registered under section 8 of the Investment Company Act of 1940 (15
U.S.C. 80a-8).
|
|
(e)
|
o
|
An
investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
(f)
|
o
|
An
employee benefit plan or endowment fund in accordance with
§240.13d-1(b)(1)(ii)(F);
|
|
(g)
|
o
|
A
parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
(h)
|
o
|
A
savings association as defined in Section 3(b) of the Federal Deposit
Insurance Act (12 U.S.C. 1813);
|
|
(i)
|
o
|
A
church plan that is excluded from the definition of an investment company
under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.
80a-3);
|
|
(j)
|
o
|
Group,
in accordance with §240.13d-1(b)(1)(ii)(J).
|
|
Not
applicable.
|
4
CUSIP
No. 921659108
|
|
Item 4.
|
Ownership
|
Provide
the following information regarding the aggregate number and percentage of
the class of securities of the issuer identified in Item 1.
|
|
(a)
|
Amount
beneficially owned:
Versant Capital Management
LLC: 0 shares
Herriot Tabuteau: 0 shares
|
|
(b)
|
Percent
of class:
Versant
Capital Management LLC: 0.00%
Herriot
Tabuteau: 0.0%
|
|
(c)
|
Number
of shares as to which the person has:
|
|
|
(i)
|
Sole
power to vote or to direct the vote
Versant Capital
Management LLC: 0
Herriot
Tabuteau: 0
|
|
|
(ii)
|
Shared
power to vote or to direct the vote
Versant
Capital Management LLC: 0
Herriot
Tabuteau: 0
|
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of
Versant
Capital Management LLC: 0
Herriot
Tabuteau: 0
|
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of
Versant
Capital Management LLC: 0
Herriot
Tabuteau: 0
|
|
Item 5.
|
Ownership
of Five Percent or Less of a Class
|
If this statement is being
filed to report the fact that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five percent of the class of
securities, check the following
x
.
|
|
Item 6.
|
Ownership
of More than Five Percent on Behalf of Another Person
|
|
Not
applicable.
|
|
Item 7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being
Reported on By the Parent Holding Company or Control Person
|
|
Not
applicable.
|
|
Item 8.
|
Identification
and Classification of Members of the Group
|
|
Not
applicable.
|
|
Item 9.
|
Notice of
Dissolution of Group
|
|
Not
applicable.
|
5
CUSIP
No. 921659108
|
|
Item 10.
|
Certification
|
|
Not
applicable.
|
SIGNATURE
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set
forth in this statement is true, complete and correct.
Date: March 6,
2008
|
|
|
|
|
|
|
|
|
|
VERSANT
CAPITAL MANAGEMENT LLC.
|
|
|
|
|
|
By:
|
/s/
Herriot Tabuteau
|
|
|
Name:
|
Herriot
Tabuteau
|
|
|
Title:
|
Managing
Member
|
|
|
|
|
|
|
|
|
/s/ Herriot
Tabuteau
|
|
|
Herriot
Tabuteau
|
|
|
|
|
|
6
Exhibit 1
JOINT
FILING AGREEMENT
JOINT FILING AGREEMENT, dated as of the 6th day of
March, 2008, among Versant Capital Management LLC and
Herriot Tabuteau
(collectively, the Reporting Persons).
WHEREAS, pursuant to Rule 13d-1(k) under
the Securities Exchange Act of 1934, as amended (the Exchange Act), the
parties hereto desire to satisfy any filing obligation under Section 13(d) of
the Exchange Act by a single joint filing;
NOW, THEREFORE, in consideration of the premises and
the mutual covenants herein contained, the Reporting Persons hereby agree and
represent as follows:
1.
Schedule 13G with respect to the Common
Stock, par value $0.01 per share, of Vanda Pharmaceuticals Inc. (to which this
Joint Filing Agreement is an exhibit) is filed on behalf of each of the
Reporting Persons.
2.
Each of the Reporting Persons is eligible to
use Schedule 13G for the filing of information contained therein.
3.
Each of the Reporting Persons is responsible
for the timely filing of Schedule 13G and any amendments thereto, and for the
completeness and accuracy of the information concerning such Person contained
therein, provided that each such Person is not responsible for the completeness
or accuracy of the information concerning any of the other Reporting Persons,
unless such Person knows or has reason to believe that such information is
inaccurate.
IN WITNESS WHEREOF, the undersigned have caused this
Joint Filing Agreement to be duly executed and delivered as of the date first
above written.
|
Versant Capital Management LLC
|
|
|
|
|
|
By:
|
/s/
Herriot Tabuteau
|
|
|
Name:
|
Herriot Tabuteau
|
|
|
Title:
|
Managing Member
|
|
|
|
|
|
|
|
/s/
Herriot Tabuteau
|
|
Herriot Tabuteau
|
7
Appendix 1
Address
of principal business office and citizenship or place of organization of each
Reporting Person required by Items 2(b) and (c).
NAME OF PERSON FILING
|
|
ADDRESS OF PRINCIPAL
BUSINESS OFFICE
|
|
CITIZENSHIP OR PLACE
OF ORGANIZATION
|
|
|
|
|
|
Versant Capital Management LLC
|
|
45 Rockefeller Plaza
Suite 2074
New York, New York 10111
|
|
Delaware
limited Liability Company
|
|
|
|
|
|
Herriot Tabuteau
|
|
c/o Antecip Capital LLC
630 5th Avenue
Suite 2074
New York, New York 10111
|
|
United
States citizen
|
8
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024